Emily Menendez

DocwireNews

Hypofractionated radiotherapy (RT) can shorten the duration of a patient&rsquo;s treatment course by utilizing fewer treatments at higher doses, but the procedure may result in more side effects.The randomized, clinical NRG-GU003 trial by Mark K. Buyyounouski, MD, MS, and colleagues examined the outcomes of patients with prostate cancer who underwent hypofractionated postprostatectomy radiotherapy (HYPORT) or conventionally fractionated postprostatectomy radiotherapy (COPORT) to determine if HYPORT is noninferior to COPORT <a href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2816344" target="_blank" rel="noopener">regarding patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms.</a>The phase 3 trial recruited 296 postprostatectomy patients between June 2017 and July 2018 who had a detectable prostate-specific antigen (PSA) level &ge;0.1 ng/mL with pT2/3pNX/0 disease, or an undetectable PSA &lt;0.1 ng/mL with either pT3 disease or pT2 disease with a positive surgical margin.Patients were randomized to receive either 62.5 Gy in 25 fractions (HYPORT) or 66.6 Gy in 37 fractions (COPORT). Primary end points included 2-year change in score from baseline for both the bowel and urinary domains of the Expanded Prostate Cancer Composite Index questionnaire. Secondary end points included a comparison between treatment arms of freedom from biochemical failure, time to progression, distant metastasis, and overall survival, among others.A total of 144 patients were placed in the HYPORT treatment group, and 152 received COPORT. The median patient age was 65 years. At the conclusion of RT, the difference between the mean GU change scores among both treatment arms was not clinically or statistically significant and remained the same at 6 and 12 months. However, the mean GI change scores in both arms were each clinically significant and different in statistical significance (&minus;15.52 [18.43] and &minus;7.06 [12.78], respectively; P&lt;.001). These differences between the HYPORT and COPORT mean GI change scores were resolved at 6 and 12 months.The 24-month differences in the mean GU and GI change scores for the HYPORT treatment arm were noninferior to the COPORT arm through noninferiority margins of &minus;5 and &minus;6, respectively, demonstrating that the hypothesis of inferiority was null (mean [SD] GU score: HYPORT, &minus;5.01 [15.10] and COPORT, &minus;4.07 [14.67]; P=.005; mean [SD] GI score: HYPORT, &minus;4.17 [10.97] and COPORT, &minus;1.41 [8.32]; P=.02). With a median follow-up for censored patients of 2.1 years, there was no difference between HYPORT and COPORT for biochemical failure, defined as a PSA of 0.4 ng/mL or higher and rising (2-year rate, 12% vs 8%; P=.28).While HYPORT was linked to a higher occurrence of patient-reported GI toxic effects compared with COPORT, both groups recovered to baseline levels within 6 months. At 2 years, HYPORT was found to be noninferior to COPORT regarding patient-reported GU or GI toxic side effects, demonstrating that HYPORT can act as an acceptable practice for patients undergoing postprostatectomy radiotherapy.

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

GI Symptoms of Hypofractionated Versus Conventional Radiotherapy

Gastroenterology

The NRG-GU003 trial examined the outcomes of patients with prostate cancer who underwent hypofractionated radiotherapy or conventional radiotherapy.

GI Symptoms of Hypofractionated vs Conventional Radiotherapy

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe